Geriatrik Nefroloji

EnglishTürkçe

BÖLÜM


DOI :10.26650/B/CH12CH47.2023.014.12   IUP :10.26650/B/CH12CH47.2023.014.12    Tam Metin (PDF)

Geri̇atri̇k Popülasyonda Glomerülonefri̇tler Ve İmmünosupressi̇f Tedavi̇ Yöneti̇mi̇

Ali Rıza Uçar, Savaş Öztürk

Yaşam beklentisinin artışı ve buna paralel olarak yaşlı nüfusun artmasıyla geriatrik popülasyondaki hastalıklar artık toplumdaki hastalıkların büyük bir kısmını oluşturmaktadır. Yaşla birlikte tGFH düşüşü, başta kardiyovasküler hastalıklar olmak üzere sistemik hastalıkların artışı, medikal ve cerrahi tedavilerin nefrotoksik etkilerinin artışı, ürolojik problemlerin artışı gibi nedenlere bağlı olarak bu popülasyonda böbrek hastalığı insidansı artmıştır1 . Bununla birlikte akut ve kronik glomerüler hastalıklar yaşlılarda mortalite ve hastane yatışının yaygın nedenlerindendir.2 Yaşlılarda gözlenen glomerüler hastalıkların tipleri, genel popülasyondakiler ile sıklıkla benzerdir, fakat klinik seyir, morfolojik bulgular ve tedavi yaklaşımı farklılıklar gösterebilir. Komorbid hastalıklar, kısa yaşam beklentisi, biyopsi komplikasyonları, immunosupressif ilaçların etkileri, yaşlılarda klinik çalışmalar ve kılavuzların yetersizliği nedeniyle tanı ve tedavi aşamasında zorluklarla karşılaşılmaktadır. Bu yüzden yaşlılardaki primer glomerüler hastalıkların genç erişkinlerdeki glomerüler hastalıklarla ayrı bir başlık altında incelenmesi gerekmektedir.3 Geriatrik popülasyondaki hastalarda glomerülonefritin diğer yaş gruplarından farklılıkları Tablo 1’de özetlenmiştir.



Referanslar

  • 1. Moutzouris DA, Herlitz L, Appel GB et al. Renal biopsy in the very elderly. Clin J Am Soc Nephrol. 2009; 4: 1073-82. google scholar
  • 2. Glassock RJ. An update on glomerular disease in the elderly. Clin Geriatr Med. 2013; 29: 579-91. google scholar
  • 3. Sumnu A, Gursu M, Ozturk S. Primary glomerular diseases in the elderly. World J Nephrol. 2015; 4: 263-70. google scholar
  • 4. Ozturk S, Sumnu A, Seyahi N et al. Demographic and clinical characteristics of primary glomerular diseases in Turkey. Int Urol Nephrol. 2014; 46: 2347-55. google scholar
  • 5. Rule AD, Amer H, Cornell LD et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med. 2010; 152: 561-7. google scholar
  • 6. Abrass CK. Glomerular Disease in the Elderly. Geriatric Nephrology Curriculum: American Society of Nephrology; 2015. google scholar
  • 7. Krenzien F, Gabardi S. Immunosenescence and immunosuppressive drugs in the elderly. In: Fulop T FC, Hirokawa K, Pawelec G, editor. Handbook of immunosenescence: Basic understanding and clinical impli-cations: Cham, Switzerland: Springer International Publishing; 2017: 2147-167. google scholar
  • 8. Vendemia F, Gesualdo L, Schena FP, D’Amico G, Renal Immunopathology Study Group of the Italian Society of N. Epidemiology of primary glomerulonephritis in the elderly. Report from the Italian Registry of Renal Biopsy. J Nephrol. 2001; 14: 340-52. google scholar
  • 9. Yang F, Li B, Cui W et al. A clinicopathological study of renal biopsies from 288 elderly patients: analysis based on 4,185 cases. Int Urol Nephrol. 2015; 47: 327-33. google scholar
  • 10. Perkowska-Ptasinska A, Deborska-Materkowska D, Bartczak A et al. Kidney disease in the elderly: biopsy based data from 14 renal centers in Poland. BMC Nephrol. 2016; 17: 194. google scholar
  • 11. Yokoyama H, Sugiyama H, Sato H et al. Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012; 16: 903-20. google scholar
  • 12. Carmo PA, Kirsztajn GM, Carmo WB, Franco MF, Bastos MG. Histopathological findings in elderly pa-tients. J Bras Nefrol. 2010; 32: 286-91. google scholar
  • 13. Bomback AS, Herlitz LC, Markowitz GS. Renal biopsy in the elderly and very elderly: useful or not? Adv Chronic Kidney Dis. 2012; 19: 61-7. google scholar
  • 14. Saeki T, Kawano M. IgG4-related kidney disease. Kidney Int. 2014; 85: 251-7. google scholar
  • 15. Gul CB, Kucuk M, Ozturk S et al. Trends of primary glomerular disease in Turkey: TSN-GOLD registry report. Int Urol Nephrol. 2022; 54: 2285-94. google scholar
  • 16. Rollino C, Ferro M, Beltrame G et al. Renal biopsy in patients over 75: 131 cases. Clin Nephrol. 2014; 82: 225-30. google scholar
  • 17. Omokawa A, Komatsuda A, Nara M et al. Renal biopsy in patients aged 80 years and older: a single-center experience in Japan. Clin Nephrol. 2012; 77: 461-7. google scholar
  • 18. Parrish AE. Complications of percutaneous renal biopsy: a review of 37 years’ experience. Clin Nephrol. 1992; 38: 135-41. google scholar
  • 19. Whittier WL, Korbet SM. Timing of complications in percutaneous renal biopsy. J Am Soc Nephrol. 2004; 15: 142-7. google scholar
  • 20. Glassock RJ. Glomerular disease in the elderly population. Geriatr Nephrol Urol. 1998; 8: 149-54. google scholar
  • 21. Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996; 49: 800-5. google scholar
  • 22. Barzilay JI, Fitzpatrick AL, Luchsinger J et al. Albuminuria and dementia in the elderly: a community study. Am J Kidney Dis. 2008; 52: 216-26. google scholar
  • 23. Abrass CK. Clinical spectrum and complications of the nephrotic syndrome. J Investig Med. 1997; 45: 14353. google scholar
  • 24. Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100: 1-276. google scholar
  • 25. Krenzien F, ElKhal A, Quante M et al. A Rationale for Age-Adapted Immunosuppression in Organ Transplantation. Transplantation. 2015; 99: 2258-68. google scholar
  • 26. Jacobson PA, Schladt D, Oetting WS et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012; 12: 3326-36. google scholar
  • 27. Ivulich S, Snell G. Long-term management of elderly patients taking immunosuppressive medications. Aust J Gen Pract. 2020; 49: 100-6. google scholar
  • 28. Nair N, Gongora E, Mehra MR. Long-term immunosuppression and malignancy in thoracic transplantation: where is the balance? J Heart Lung Transplant. 2014; 33: 461-7. google scholar
  • 29. Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation. 1999; 68: 1859-64. google scholar
  • 30. Christians U, Klawitter J, Clavijo CF. Bioequivalence testing of immunosuppressants: concepts and mis-conceptions. Kidney Int Suppl. 2010; 115: 1-7. google scholar
  • 31. Ronco P, Beck L, Debiec H et al. Membranous nephropathy. Nat Rev Dis Primers. 2021; 7: 69. google scholar
  • 32. Polanco N, Gutierrez E, Covarsi A et al. Spontaneous remission of nephrotic syndrome in idiopathic memb-ranous nephropathy. J Am Soc Nephrol. 2010; 21: 697-704. google scholar
  • 33. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomeru-lonephritis. Kidney Int. 1992; 42: 960-6. google scholar
  • 34. Mahmud M, Pinnschmidt HO, Reinhard L et al. Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy. PLoS One. 2019; 14: e0221293. doi: 10.1371/journal.pone.0221293. google scholar
  • 35. Smith JD, Hayslett JP. Reversible renal failure in the nephrotic syndrome. Am J Kidney Dis. 1992; 19: 20113. google scholar
  • 36. O’Callaghan CA, Hicks J, Doll H, Sacks SH, Cameron JS. Characteristics and outcome of membranous nephropathy in older patients. Int Urol Nephrol. 2002; 33: 157-65. google scholar
  • 37. Yamaguchi M, Ando M, Yamamoto R et al. Patient age and the prognosis of idiopathic membranous neph-ropathy. PLoS One. 2014; 9: e110376. doi: 10.1371/journal.pone.0110376. google scholar
  • 38. Hofstra JM, Wetzels JF. Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues. J Am Soc Nephrol. 2014; 25: 1137-9. google scholar
  • 39. Abrass CK. Treatment of membranous nephropathy in the elderly. Semin Nephrol. 2003; 23: 373-8. google scholar
  • 40. An S De Vriese, Daniel C Cattran. Membranous nephropathy: Treatment and prognosis. In: TW P, editor. UpToDate. Waltham, MA: UpToDate; 2022. google scholar
  • 41. Waldman M, Crew RJ, Valeri A et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007; 2: 445-53. google scholar
  • 42. Nagai R, Cattran DC, Pei Y. Steroid therapy and prognosis of focal segmental glomerulosclerosis in the elderly. Clin Nephrol. 1994; 42: 18-21. google scholar
  • 43. Gutierrez E, Praga M, Rivera F et al. Changes in the clinical presentation of immunoglobulin A nephropathy: data from the Spanish Registry of Glomerulonephritis. Nephrol Dial Transplant. 2018; 33: 472-7. google scholar
  • 44. Frimat L, Hestin D, Aymard B, Mayeux D, Renoult E, Kessler M. IgA nephropathy in patients over 50 years of age: a multicentre, prospective study. Nephrol Dial Transplant. 1996; 11: 1043-7. google scholar
  • 45. Cheungpasitporn W, Nasr SH, Thongprayoon C, Mao MA, Qian Q. Primary IgA nephropathy in elderly patients. Nephrology (Carlton). 2015; 20: 419-25. google scholar
  • 46. Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2017; 318: 432-42. google scholar
  • 47. Rauen T, Eitner F, Fitzner C et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015; 373: 2225-36. google scholar
  • 48. Lv J, Wong MG, Hladunewich MA et al. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2022;327: 1888-98. google scholar
  • 49. Pagnoux C, Quemeneur T, Ninet J et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015; 67: 1117-27. google scholar
  • 50. Furuta S, Nakagomi D, Kobayashi Y et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021; 325: 2178-87. google scholar


PAYLAŞ




İstanbul Üniversitesi Yayınları, uluslararası yayıncılık standartları ve etiğine uygun olarak, yüksek kalitede bilimsel dergi ve kitapların yayınlanmasıyla giderek artan bilimsel bilginin yayılmasına katkıda bulunmayı amaçlamaktadır. İstanbul Üniversitesi Yayınları açık erişimli, ticari olmayan, bilimsel yayıncılığı takip etmektedir.